<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010396711</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010396711</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacokinetics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modeling the Kinetics of Digoxin Absorption</article-title>
<subtitle>Enhancement by P-Glycoprotein Inhibition</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Weiss</surname><given-names>Michael</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Sermsappasuk</surname><given-names>Pakawadee</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Siegmund</surname><given-names>Werner</given-names></name>
<degrees>MD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270010396711">Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand (Dr Weiss, Dr Sermsappasuk)</aff>
<aff id="aff2-0091270010396711">Department of Pharmacology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (Dr Weiss)</aff>
<aff id="aff3-0091270010396711">Division of Clinical Pharmacology, Institute of Pharmacology, Ernst Moritz Arndt University, Greifswald, Germany (Dr Siegmund)</aff>
<author-notes>
<corresp id="corresp1-0091270010396711">Michael Weiss, PhD, Department of Pharmacology, Martin Luther University Halle-Wittenberg, D-06097 Halle (Saale), Germany; e-mail: <email>michael.weiss@medizin.uni-halle.de</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>3</issue>
<fpage>381</fpage>
<lpage>387</lpage>
<history>
<date date-type="received">
<day>1</day>
<month>9</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>12</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>An increase in the area under the curve (AUC) after oral digoxin due to coadministration of drugs known as P-glycoprotein (P-gp) inhibitors has been reported in several studies, but there is very little information on the rate of absorption after P-gp inhibition. Based on an inverse Gaussian density absorption model and using a population approach, the authors reanalyzed data showing an increase in oral digoxin AUC in healthy volunteers after coadministration of talinolol. The model fitted the data well, and the results revealed that the maximum rate of digoxin absorption increased nearly 2-fold, whereas bioavailability increased only by 21%. It is concluded that the increase in the rate of absorption seems to be a better indicator of intestinal P-gp inhibition than the increase in extent of absorption. Furthermore, the authors use a simulation study to demonstrate the ability of the method to estimate bioavailability based on the population characteristics of digoxin disposition kinetics obtained from a different group of healthy volunteers.</p>
</abstract>
<kwd-group>
<kwd>P-glycoprotein inhibition</kwd>
<kwd>digoxin</kwd>
<kwd>bioavailability</kwd>
<kwd>absorption rate</kwd>
<kwd>population pharmacokinetics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Digoxin is one of the most widely prescribed cardiac drugs. Because of its very narrow therapeutic range of 0.5 to 0.9 ng/mL,<sup><xref ref-type="bibr" rid="bibr1-0091270010396711">1</xref></sup> it is important to understand the underlying cause of pharmacokinetic variability. P-glycoprotein (P-gp), an efflux transporter limiting the intestinal absorption of digoxin, plays a major role in this respect. It has been shown that the area under the plasma concentration time curve (AUC) of oral digoxin correlated negatively with P-gp expression in the duodenum.<sup><xref ref-type="bibr" rid="bibr2-0091270010396711">2</xref></sup> Thus, inhibition of P-gp by other drugs may increase absorption of digoxin and can result in adverse reactions. An increase in digoxin bioavailability has been reported after coadministration of amiodarone,<sup><xref ref-type="bibr" rid="bibr3-0091270010396711">3</xref></sup> verapamil,<sup><xref ref-type="bibr" rid="bibr4-0091270010396711">4</xref></sup> carvedilol,<sup><xref ref-type="bibr" rid="bibr5-0091270010396711">5</xref></sup> quinidine,<sup><xref ref-type="bibr" rid="bibr6-0091270010396711">6</xref>,<xref ref-type="bibr" rid="bibr7-0091270010396711">7</xref></sup> valspodar,<sup><xref ref-type="bibr" rid="bibr8-0091270010396711">8</xref></sup> talinolol,<sup><xref ref-type="bibr" rid="bibr9-0091270010396711">9</xref></sup> atorvastatine,<sup><xref ref-type="bibr" rid="bibr10-0091270010396711">10</xref></sup> itraconazole,<sup><xref ref-type="bibr" rid="bibr11-0091270010396711">11</xref></sup> dipyridamole,<sup><xref ref-type="bibr" rid="bibr12-0091270010396711">12</xref></sup> Cremophor RH40,<sup><xref ref-type="bibr" rid="bibr13-0091270010396711">13</xref></sup> and ritonavir.<sup><xref ref-type="bibr" rid="bibr14-0091270010396711">14</xref></sup> However, in all of these studies, only plasma AUC was calculated, and the studies provided no information concerning the rate of digoxin absorption. Therefore, the aim of this study was to quantify the change in digoxin absorption rate caused by P-gp inhibition. To this end, we reanalyzed previously published data describing the increase of oral digoxin AUC in healthy volunteers after coadministration of talinolol.<sup><xref ref-type="bibr" rid="bibr9-0091270010396711">9</xref></sup> The data were fitted using a population approach and an inverse Gaussian density absorption model.<sup><xref ref-type="bibr" rid="bibr15-0091270010396711">15</xref>,<xref ref-type="bibr" rid="bibr16-0091270010396711">16</xref></sup> Since no intravenous data as reference were available in these subjects, our primary aim was to quantify the relative changes in absorption parameters after P-gp inhibition. In addition, we also attempted to estimate the absolute bioavailability in the control experiment using prior information about digoxin disposition parameters from the literature.</p>
<sec id="section1-0091270010396711" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010396711">
<title>Data and Study Protocol</title>
<p>The study protocol has been described before.<sup><xref ref-type="bibr" rid="bibr9-0091270010396711">9</xref></sup> Here, we refer only to the data used in this analysis. In brief, in a randomized crossover study with a washout period of at least 7 weeks, 10 healthy volunteers received a single dose of 0.5 mg digoxin (2 tablets Lanicor, Boehringer Mannheim, Germany) alone and concomitantly with oral talinolol (100 mg). The tablets were given with 100 mL tap water (room temperature) after overnight fasting. Venous blood samples were collected before and 0.25, 0.5, 0.75, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours after administration of the tablets. Serum digoxin concentrations were determined by an automatic fluorescence polarization immunoassay (TDxFLx; Abbott Labora-tories, Abbott Park, Illinois). The limit of quantification was 0.1 ng/mL.</p>
</sec>
<sec id="section3-0091270010396711">
<title>Pharmacokinetic Model</title>
<p>As in our previous articles, we use the inverse Gaussian function as an empirical model of the absorption process<sup><xref ref-type="bibr" rid="bibr15-0091270010396711">15</xref>,<xref ref-type="bibr" rid="bibr16-0091270010396711">16</xref></sup>:</p>
<p>
<disp-formula id="disp-formula1-0091270010396711">
<label>(1)</label>
<mml:math display="block" id="math1-0091270010396711">
<mml:msub>
<mml:mi>f</mml:mi>
<mml:mi>A</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>D</mml:mi>
<mml:mi>F</mml:mi>
<mml:msqrt>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>T</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mi>π</mml:mi>
<mml:mi>C</mml:mi>
<mml:msubsup>
<mml:mi>V</mml:mi>
<mml:mi>A</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
<mml:msup>
<mml:mi>t</mml:mi>
<mml:mn>3</mml:mn>
</mml:msup>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
</mml:msqrt>
<mml:mi>exp</mml:mi>
<mml:mo>⁡</mml:mo>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msup>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mi>C</mml:mi>
<mml:msubsup>
<mml:mi>V</mml:mi>
<mml:mi>A</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>T</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula1-0091270010396711" xlink:href="10.1177_0091270010396711-eq1.tif"/></disp-formula>
</p>
<p>where <italic>MAT</italic> represents the mean absorption time and <inline-formula id="inline-formula1-0091270010396711">
<mml:math display="inline" id="math2-0091270010396711">
<mml:mi>C</mml:mi>
<mml:msubsup>
<mml:mi>V</mml:mi>
<mml:mi>A</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula> is a normalized variance or relative dispersion of absorption times. The factor <italic>F</italic> is the bioavailability of the orally administered dose <italic>D</italic>. Note that <xref ref-type="disp-formula" rid="disp-formula1-0091270010396711">equation 1</xref> describes the rate of absorption, which reaches its maximum at time</p>
<p>
<disp-formula id="disp-formula2-0091270010396711">
<label>(2)</label>
<mml:math display="block" id="math3-0091270010396711">
<mml:msub>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mi>A</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>max</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msqrt>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mfrac>
<mml:mn>9</mml:mn>
<mml:mn>4</mml:mn>
</mml:mfrac>
<mml:mi>C</mml:mi>
<mml:msubsup>
<mml:mi>V</mml:mi>
<mml:mi>A</mml:mi>
<mml:mn>4</mml:mn>
</mml:msubsup>
</mml:mrow>
</mml:msqrt>
<mml:mo>−</mml:mo>
<mml:mfrac>
<mml:mn>3</mml:mn>
<mml:mn>2</mml:mn>
</mml:mfrac>
<mml:mi>C</mml:mi>
<mml:msubsup>
<mml:mi>V</mml:mi>
<mml:mi>A</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0091270010396711" xlink:href="10.1177_0091270010396711-eq2.tif"/></disp-formula>
</p>
<p>and the maximum rate of absorption, <italic>f<sub>A,max</sub></italic>, can be calculated by substituting <italic>t<sub>A,max</sub></italic> into <xref ref-type="disp-formula" rid="disp-formula1-0091270010396711">equation 1</xref>. The time course of the fraction absorbed is obtained from the absorption rate (<xref ref-type="disp-formula" rid="disp-formula1-0091270010396711">equation 1</xref>) as</p>
<p>
<disp-formula id="disp-formula3-0091270010396711">
<label>(3)</label>
<mml:math display="block" id="math4-0091270010396711">
<mml:msub>
<mml:mi>F</mml:mi>
<mml:mi>A</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mstyle displaystyle="true">
<mml:mrow>
<mml:munderover>
<mml:mo>∫</mml:mo>
<mml:mn>0</mml:mn>
<mml:mi>t</mml:mi>
</mml:munderover>
<mml:mrow>
<mml:msub>
<mml:mi>f</mml:mi>
<mml:mi>A</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>τ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>τ</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mstyle>
</mml:math>
<graphic alternate-form-of="disp-formula3-0091270010396711" xlink:href="10.1177_0091270010396711-eq3.tif"/></disp-formula>
</p>
<p>with <italic>F<sub>A</sub></italic>(∞) = <italic>F</italic>.</p>
<p>For comparison, the data are also analyzed assuming first-order absorption (as the most simple and commonly used model).</p>
<p>The disposition process (ie, the digoxin concentration-time curve following an intravenous bolus dose) is described by a 3-compartment model<sup><xref ref-type="bibr" rid="bibr17-0091270010396711">17</xref></sup> with parameter clearance (<italic>CL</italic>), distribution volumes (<italic>V</italic><sub>0</sub>, <italic>V</italic><sub>1</sub>, <italic>V</italic><sub>2</sub>), and distribution clearances (<italic>CL</italic><sub>01</sub>, <italic>CL</italic><sub>02</sub>).</p>
</sec>
<sec id="section4-0091270010396711">
<title>Parameter Estimation</title>
<p>Population analysis was employed to improve the reliability of parameter estimation. This method has proven successful when parameters are poorly estimated using individual fits. Data fitting (population analysis) was carried out with maximum likelihood estimation via the EM algorithm using the software ADAPT 5 where the program (MLEM) is implemented.<sup><xref ref-type="bibr" rid="bibr18-0091270010396711">18</xref></sup> The program provides estimates of the population mean and intersubject variability as well as of the individual subject parameters (conditional means). It was assumed that the model parameters were log-normally distributed among subjects and that the measurement error had a standard deviation that was a linear function of the measured quantity. (Note that the model used here is available in the ADAPT Model Library as igabs.for.) Goodness of fit was evaluated by Akaike’s information criterion (AIC) and by plotting the predicted versus the measured concentration. One complicating factor in the present case was the lack of intravenous data. Thus, we tested an empirical approach using the digoxin disposition data of 5 healthy male volunteers reported by Kramer et al,<sup><xref ref-type="bibr" rid="bibr17-0091270010396711">17</xref></sup> where 21 blood samples were taken between 2 minutes and 72 hours after rapid intravenous injection of a 1-mg dose of digoxin. First, these data were fitted and the estimates (means and interindividual variability) of the disposition parameters were used to define prior probability distribution on which the population fit of the oral data (digoxin alone) was based. Note that the results of the MLEM fit are dependent on this prior probability distribution rather than the starting values. The 6 disposition parameters, CL, V<sub>0</sub>, V<sub>1</sub>, V<sub>2</sub>, CL<sub>01</sub>, and CL<sub>02</sub>, estimated for each subject (conditional means), were then fixed in fitting the concentration-time data obtained in the presence of talinolol (P-gp inhibition) to estimate the 3 absorption parameters: F, MAT, and <inline-formula id="inline-formula2-0091270010396711">
<mml:math display="inline" id="math5-0091270010396711">
<mml:mi>C</mml:mi>
<mml:msubsup>
<mml:mi>V</mml:mi>
<mml:mi>A</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula>. We found that treating CL as an additional adjustable parameter did not improve the fit.</p>
<p>The paired <italic>t</italic> test was applied to the individual subject parameters (conditional means) to evaluate the effect of talinolol. If the <italic>P</italic> value was &lt;.05, the difference was considered to be significant.</p>
</sec>
<sec id="section5-0091270010396711">
<title>Simulations</title>
<p>It is clear that intravenous administration of the drug in the same subject is a condition for estimating the absolute bioavailability. To test the usefulness of our method, which is based on a prior probability distribution for digoxin disposition parameters estimated using data from other individuals, we have applied this approach to analyze simulated data sets (ie, oral data where the absolute bioavailability was known). A population simulation of concentration-time profiles for digoxin (20 subjects) was performed with the simulation module of ADAPT 5 using the parameters and the residual error estimated in the control subjects. The estimation procedure was then exactly that used for the real data. This was repeated 10 times (100 simulations), and bias (%) was defined as 100 × (parameter estimate – known parameter value)/known parameter value. Precision was calculated as percentage absolute error. To test the dependence on the initial guess of bioavailability (<italic>F</italic> = 0.8), we have repeated this procedure assuming <italic>F</italic> = 0.4 instead of 0.67.</p>
</sec>
</sec>
<sec id="section6-0091270010396711" sec-type="results">
<title>Results</title>
<p>The inverse Gaussian absorption model fitted the serum concentration data in the control experiment very well (AIC = −184). All individual fits are depicted in <xref ref-type="fig" rid="fig1-0091270010396711">Figure 1</xref>. The goodness-of-fit plot (<xref ref-type="fig" rid="fig2-0091270010396711">Figure 2A</xref>) shows that the individual predicted concentrations were in good agreement with the observed ones, with a regression line (not shown) close to the line of identity (slope = 1.02 ± 0.02, intercept = −0.02 ± 0.02, <italic>R</italic><sup>2</sup> = 0.953). That the conventional first-order model fitted the data worse is evidenced by the larger scatter in the observed versus predicted plot (<xref ref-type="fig" rid="fig2-0091270010396711">Figure 2B</xref>) and the parameters of the regression line (slope = 1.08 ± 0.03, intercept = −0.06 ± 0.03, <italic>R</italic><sup>2</sup> = 0.871), as well as the higher AIC score of −52. The population parameters for digoxin are summarized in <xref ref-type="table" rid="table1-0091270010396711">Table I</xref>. Note that due to the mismatch between the number of adjustable parameters and the number of subjects, standard errors of population parameters (%RSE) were not available when first fitting the digoxin data of the control subjects. Coadministration of talinolol induced a significant change in all absorption parameters of digoxin: the maximum rate of digoxin absorption and bioavailability increased significantly from 278 ± 71 to 498 ± 171 µg/h (<italic>P</italic> &lt; .01) and from 67.1% ± 9% to 81.2% ± 8% (<italic>P</italic> &lt; .05), respectively (see <xref ref-type="fig" rid="fig3-0091270010396711">Figure 3</xref>), whereas the mean absorption time and the dispersion of absorption time distribution decreased from 1.32 ± 0.22 to 0.88 ± 0.28 h (<italic>P</italic> &lt; .01) and from 0.89 ± 0.33 to 0.45 ± 0.28 (<italic>P</italic> &lt; .05), respectively. That our method to estimate the absolute bioavailability in the control experiment appears to be relatively accurate is indicated in the mean bias (overestimation) of <italic>F</italic> of 11% ± 3% determined in the simulation study. The dependence of the <italic>F</italic> estimate on the initial guess (<italic>F</italic> = 0.8) is reflected in the higher overestimation of 23% ± 7% obtained in assuming <italic>F</italic> = 0.4.</p>
<fig id="fig1-0091270010396711" position="float">
<label>Figure 1.</label>
<caption><p>Fits of serum digoxin concentration of all subjects (without talinolol) based on estimates for the individual subject parameters (conditional means) obtained with the inverse Gaussian absorption and 3-compartment disposition model.</p></caption>
<graphic xlink:href="10.1177_0091270010396711-fig1.tif"/>
</fig>
<fig id="fig2-0091270010396711" position="float">
<label>Figure 2.</label>
<caption><p>Goodness-of-fit plots for the (A) inverse Gaussian absorption model and (B) the first-order absorption model. Observed concentrations are plotted versus individual predictions (data from all 10 subjects without talinolol). The solid line represents the line of identity.</p></caption>
<graphic xlink:href="10.1177_0091270010396711-fig2.tif"/>
</fig>
<table-wrap id="table1-0091270010396711" position="float">
<label>Table I</label>
<caption><p>Parameter Estimates for the Model of Digoxin Absorption Kinetics From Fitting of Digoxin Plasma Concentration Data in Healthy Volunteers Following Orally Administered Digoxin (0.5 mg) Without and With Coadministration of 100 mg Oral Talinolol (n = 10)</p></caption>
<graphic alternate-form-of="table1-0091270010396711" xlink:href="10.1177_0091270010396711-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Digoxin Alone</th>
<th align="center" colspan="2">Digoxin + Talinolol</th>
</tr>
<tr>
<th align="left">Treatment and Parameter</th>
<th align="center">Population Mean</th>
<th align="center">Interpatient %CV</th>
<th align="center">Population Mean (%RSE)</th>
<th align="center">Interpatient %CV (%RSE)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">Absorption</td>
</tr>
<tr>
<td> MAT, h</td>
<td>1.32</td>
<td>17</td>
<td>0.88 (20)<xref ref-type="table-fn" rid="table-fn3-0091270010396711">**</xref></td>
<td>31 (50)</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula3-0091270010396711">
<mml:math display="inline" id="math6-0091270010396711">
<mml:mi>C</mml:mi>
<mml:msubsup>
<mml:mi>V</mml:mi>
<mml:mi>A</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.89</td>
<td>38</td>
<td>0.45 (51)<xref ref-type="table-fn" rid="table-fn3-0091270010396711">*</xref></td>
<td>63 (92)</td>
</tr>
<tr>
<td> F, %</td>
<td>67.1</td>
<td>14</td>
<td>81.2 (17)<xref ref-type="table-fn" rid="table-fn3-0091270010396711">*</xref></td>
<td>9 (66)</td>
</tr>
<tr>
<td> f<sub>A,max</sub>, µg/h<sup><xref ref-type="table-fn" rid="table-fn2-0091270010396711">a</xref></sup></td>
<td>278</td>
<td>26</td>
<td>499<xref ref-type="table-fn" rid="table-fn3-0091270010396711">**</xref></td>
<td>34</td>
</tr>
<tr>
<td>Disposition</td>
<td>332</td>
<td>40</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> V<sub>0</sub>, L</td>
<td>48.8</td>
<td>34</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> V<sub>1</sub>, L</td>
<td>84</td>
<td>62</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> V<sub>2</sub>, L</td>
<td>540</td>
<td>8</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> CL<sub>01</sub>, L/h</td>
<td>76.5</td>
<td>22</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> CL<sub>02</sub>, L/h</td>
<td>43.8</td>
<td>14</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> CL, L/h</td>
<td>7.97</td>
<td>9</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010396711">
<p>The individual disposition parameters were fixed in fitting the data obtained in the presence of talinolol.</p>
</fn>
<fn id="table-fn2-0091270010396711">
<label>a.</label>
<p>Derived parameter (<xref ref-type="disp-formula" rid="disp-formula1-0091270010396711">equations 1</xref> and <xref ref-type="disp-formula" rid="disp-formula2-0091270010396711">2</xref>).</p>
</fn>
<fn id="table-fn3-0091270010396711">
<p>Significant differences from digoxin alone: *<italic>P</italic> &lt; .05; **<italic>P</italic> &lt; .01.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig3-0091270010396711" position="float">
<label>Figure 3.</label>
<caption><p>Simulated time courses of (A) digoxin absorption rate and (B) fraction absorbed without and with talinolol (based on the population mean parameters).</p></caption>
<graphic xlink:href="10.1177_0091270010396711-fig3.tif"/>
</fig>
</sec>
<sec id="section7-0091270010396711" sec-type="discussion">
<title>Discussion</title>
<p>Our estimate of digoxin bioavailability of 67% ± 9% obtained with our novel empirical method is higher than that of 63% ± 11% and 61% ± 5% reported by Greiner et al<sup><xref ref-type="bibr" rid="bibr2-0091270010396711">2</xref></sup> and Rengelshausen et al,<sup><xref ref-type="bibr" rid="bibr19-0091270010396711">19</xref></sup> respectively, for Lanicor tablets. By coincidence, our estimate is identical to that measured for aqueous digoxin solution<sup><xref ref-type="bibr" rid="bibr20-0091270010396711">20</xref></sup> and in accordance with the values of 68.5% ± 13%<sup><xref ref-type="bibr" rid="bibr6-0091270010396711">6</xref></sup> and 67.6% ± 4%<sup><xref ref-type="bibr" rid="bibr21-0091270010396711">21</xref></sup> estimated for tablets. Cohen et al<sup><xref ref-type="bibr" rid="bibr22-0091270010396711">22</xref></sup> found no difference in bioavailability between digoxin tablets (72%) and liquid-filled capsules (71%). Although we cannot say anything about the true bioavailability in the control subjects, our estimate, together with bias of about 10% overestimation predicted by the simulation study, suggests that our method may be useful when no intravenous reference data are available. Note that this was achieved by a realistic absorption model and using a population approach with prior information about digoxin disposition kinetics.</p>
<p>P-gp inhibition by talinolol increased the maximum rate of digoxin absorption, <italic>f<sub>A,max</sub></italic>, nearly 2-fold but bioavailability only by 21% (see <xref ref-type="fig" rid="fig3-0091270010396711">Figure 3</xref>). The lower increase of <italic>F</italic> is not surprising since it is bounded above by about 30% (<italic>F</italic> cannot exceed 100%) while there is no such limitation on <italic>f<sub>A,max</sub></italic>. Note that dissolution time appears negligible compared with absorption, given the finding that Lanicor tablets dissolved in vitro within 1.2 minutes.<sup><xref ref-type="bibr" rid="bibr13-0091270010396711">13</xref></sup> Thus, the increase in rate of absorption seems to be a better indicator of intestinal P-gp inhibition than the increase in extent of absorption. This is in accordance with findings in rats showing that P-gp inhibition increased primarily the rate of digoxin absorption.<sup><xref ref-type="bibr" rid="bibr23-0091270010396711">23</xref>,<xref ref-type="bibr" rid="bibr24-0091270010396711">24</xref></sup> We should note that our approach does not account for interoccasion parameter variability. A bias can result if this effect is not random.</p>
<p>While the clinical relevance of the increase in bioavailability has been discussed controversially, <sup><xref ref-type="bibr" rid="bibr25-0091270010396711">25</xref>,<xref ref-type="bibr" rid="bibr26-0091270010396711">26</xref></sup> a higher input rate has no effect on digoxin pharmacodynamics due to the long delay between serum concentration and action.<sup><xref ref-type="bibr" rid="bibr27-0091270010396711">27</xref></sup> P-gp inhibition not only decreased mean absorption time but also decreased the dispersion of absorption time around the mean to 64% of the control value. Among the 28 drugs compared in the work of Fenner et al<sup><xref ref-type="bibr" rid="bibr26-0091270010396711">26</xref></sup> regarding their ability to increase the digoxin AUC ratio, talinolol<sup><xref ref-type="bibr" rid="bibr9-0091270010396711">9</xref></sup> was in the lower third. This may be in accordance with the finding that talinolol shows a relatively weak inhibition of P-gp activity in vitro.<sup><xref ref-type="bibr" rid="bibr28-0091270010396711">28</xref></sup> Note that the question whether the plasma concentration of talinolol after an oral dose of 100 mg (<italic>C<sub>max</sub></italic> = 264 ± 58 ng/mL<sup><xref ref-type="bibr" rid="bibr9-0091270010396711">9</xref></sup>) was high enough to achieve maximal P-gp inhibition is primarily of theoretical rather than clinical interest.</p>
<p>In contrast to a purely AUC-based analysis, the estimation of absorption rate parameters allows us to differentiate between the effect of absorption and elimination. That in this case a change of clearance did not contribute to the AUC increase after talinolol was suggested by the fact that renal clearance remained unchanged and intravenous talinolol had no effect.<sup><xref ref-type="bibr" rid="bibr9-0091270010396711">9</xref></sup></p>
<p>In summary, the more realistic absorption model allows a quantification of the absorption process and may lead to additional insight into the effects of P-gp inhibition (or induction). The results show that population analysis can also be of advantage in the case of rich data from a relatively small group of subjects.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010396711">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>A</given-names></name>
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Rahimtoola</surname><given-names>SH</given-names></name>
<etal/>
</person-group>. <article-title>Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial</article-title>. <source>Int J Cardiol</source>. <year>2008</year>;<volume>123</volume>(<issue>2</issue>):<fpage>138</fpage>-<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010396711">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greiner</surname><given-names>B</given-names></name>
<name><surname>Eichelbaum</surname><given-names>M</given-names></name>
<name><surname>Fritz</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin</article-title>. <source>J Clin Invest</source>. <year>1999</year>;<volume>104</volume>(<issue>2</issue>):<fpage>147</fpage>-<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010396711">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santostasi</surname><given-names>G</given-names></name>
<name><surname>Fantin</surname><given-names>M</given-names></name>
<name><surname>Maragno</surname><given-names>I</given-names></name>
<name><surname>Gaion</surname><given-names>RM</given-names></name>
<name><surname>Basadonna</surname><given-names>O</given-names></name>
<name><surname>Dalla-Volta</surname><given-names>S</given-names></name>
</person-group>. <article-title>Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects</article-title>. <source>J Cardiovasc Pharmacol</source>. <year>1987</year>;<volume>9</volume>(<issue>4</issue>):<fpage>385</fpage>-<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010396711">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rodin</surname><given-names>SM</given-names></name>
<name><surname>Johnson</surname><given-names>BF</given-names></name>
<name><surname>Wilson</surname><given-names>J</given-names></name>
<name><surname>Ritchie</surname><given-names>P</given-names></name>
<name><surname>Johnson</surname><given-names>J</given-names></name>
</person-group>. <article-title>Comparative effects of verapamil and isradipine on steady-state digoxin kinetics</article-title>. <source>Clin Pharmacol Ther.</source> <year>1988</year>;<volume>43</volume>(<issue>6</issue>):<fpage>668</fpage>-<lpage>672</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010396711">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Mey</surname><given-names>C</given-names></name>
<name><surname>Brendel</surname><given-names>E</given-names></name>
<name><surname>Enterling</surname><given-names>D</given-names></name>
</person-group>. <article-title>Carvedilol increases the systemic bioavailability of oral digoxin</article-title>. <source>Br J Clin Pharmacol</source>. <year>1990</year>;<volume>29</volume>(<issue>4</issue>):<fpage>486</fpage>-<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010396711">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pedersen</surname><given-names>KE</given-names></name>
<name><surname>Christiansen</surname><given-names>BD</given-names></name>
<name><surname>Klitgaard</surname><given-names>NA</given-names></name>
<name><surname>Nielsen-Kudsk</surname><given-names>F</given-names></name>
</person-group>. <article-title>Effect of quinidine on digoxin bioavailability</article-title>. <source>Eur J Clin Pharmacol</source>. <year>1983</year>;<volume>24</volume>(<issue>1</issue>):<fpage>41</fpage>-<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010396711">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fromm</surname><given-names>MF</given-names></name>
<name><surname>Kim</surname><given-names>RB</given-names></name>
<name><surname>Stein</surname><given-names>CM</given-names></name>
<name><surname>Wilkinson</surname><given-names>GR</given-names></name>
<name><surname>Roden</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>99</volume>(<issue>4</issue>):<fpage>552</fpage>-<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010396711">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kovarik</surname><given-names>JM</given-names></name>
<name><surname>Rigaudy</surname><given-names>L</given-names></name>
<name><surname>Guerret</surname><given-names>M</given-names></name>
<name><surname>Gerbeau</surname><given-names>C</given-names></name>
<name><surname>Rost</surname><given-names>KL</given-names></name>
</person-group>. <article-title>Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin</article-title>. <source>Clin Pharmacol Ther</source>. <year>1999</year>;<volume>66</volume>(<issue>4</issue>): <fpage>391</fpage>-<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010396711">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westphal</surname><given-names>K</given-names></name>
<name><surname>Weinbrenner</surname><given-names>A</given-names></name>
<name><surname>Giessmann</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein</article-title>. <source>Clin Pharmacol Ther</source>. <year>2000</year>; <volume>68</volume>(<issue>1</issue>):<fpage>6</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010396711">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boyd</surname><given-names>RA</given-names></name>
<name><surname>Stern</surname><given-names>RH</given-names></name>
<name><surname>Stewart</surname><given-names>BH</given-names></name>
<etal/>
</person-group>. <article-title>Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion</article-title>. <source>J Clin Pharmacol</source>. <year>2000</year>;<volume>40</volume>(<issue>1</issue>):<fpage>91</fpage>-<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010396711">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Angirasa</surname><given-names>AK</given-names></name>
<name><surname>Koch</surname><given-names>AZ</given-names></name>
</person-group>. <article-title>P-glycoprotein as the mediator of itraconazole-digoxin interaction</article-title>. <source>J Am Podiatr Med Assoc.</source> <year>2002</year>;<volume>92</volume>(<issue>8</issue>):<fpage>471</fpage>-<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010396711">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verstuyft</surname><given-names>C</given-names></name>
<name><surname>Strabach</surname><given-names>S</given-names></name>
<name><surname>El-Morabet</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition</article-title>. <source>Clin Pharmacol Ther.</source> <year>2003</year>;<volume>73</volume>(<issue>1</issue>):<fpage>51</fpage>-<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010396711">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tayrouz</surname><given-names>Y</given-names></name>
<name><surname>Ding</surname><given-names>R</given-names></name>
<name><surname>Burhenne</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40</article-title>. <source>Clin Pharmacol Ther.</source> <year>2003</year>;<volume>73</volume>(<issue>5</issue>):<fpage>397</fpage>-<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010396711">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ding</surname><given-names>R</given-names></name>
<name><surname>Tayrouz</surname><given-names>Y</given-names></name>
<name><surname>Riedel</surname><given-names>KD</given-names></name>
<etal/>
</person-group>. <article-title>Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers</article-title>. <source>Clin Pharmacol Ther.</source> <year>2004</year>;<volume>76</volume>(<issue>1</issue>):<fpage>73</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010396711">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>M</given-names></name>
</person-group>. <article-title>A novel extravascular input function for the assessment of drug absorption in bioavailability studies</article-title>. <source>Pharm Res.</source> <year>1996</year>;<volume>13</volume>(<issue>10</issue>):<fpage>1547</fpage>-<lpage>1553</lpage>.</citation>
</ref>
<ref id="bibr16-0091270010396711">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Weiss</surname><given-names>M</given-names></name>
<name><surname>D’Argenio</surname><given-names>DZ</given-names></name>
</person-group>. <article-title>A note on population analysis of dissolution-absorption models using the inverse Gaussian function</article-title>. <source>J Clin Pharmacol</source>. <year>2008</year>;<volume>48</volume>(<issue>6</issue>):<fpage>719</fpage>-<lpage>725</lpage>.</citation>
</ref>
<ref id="bibr17-0091270010396711">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kramer</surname><given-names>WG</given-names></name>
<name><surname>Lewis</surname><given-names>RP</given-names></name>
<name><surname>Cobb</surname><given-names>TC</given-names></name>
<etal/>
</person-group>. <article-title>Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man</article-title>. <source>J Pharmacokinet Biopharm</source>. <year>1974</year>;<volume>2</volume>(<issue>4</issue>):<fpage>299</fpage>-<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr18-0091270010396711">
<label>18.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>D’Argenio</surname><given-names>DZ</given-names></name>
<name><surname>Schumitzky</surname><given-names>A</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
</person-group>. <source>ADAPT 5 User’s Guide: Pharmacokinetic /Pharmacodynamic Systems Analysis Software</source>. <publisher-loc>Los Angeles, CA</publisher-loc>: <publisher-name>Biomedical Simulations Resource</publisher-name>;<year>2009</year>.</citation>
</ref>
<ref id="bibr19-0091270010396711">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rengelshausen</surname><given-names>J</given-names></name>
<name><surname>Goggelmann</surname><given-names>C</given-names></name>
<name><surname>Burhenne</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction</article-title>. <source>Br J Clin Pharmacol</source>. <year>2003</year>;<volume>56</volume>(<issue>1</issue>):<fpage>32</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr20-0091270010396711">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hinderling</surname><given-names>PH</given-names></name>
<name><surname>Hartmann</surname><given-names>D</given-names></name>
</person-group>. <article-title>Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans</article-title>. <source>Ther Drug Monit</source>. <year>1991</year>;<volume>13</volume>(<issue>5</issue>):<fpage>381</fpage>-<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr21-0091270010396711">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurata</surname><given-names>Y</given-names></name>
<name><surname>Ieiri</surname><given-names>I</given-names></name>
<name><surname>Kimura</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein</article-title>. <source>Clin Pharmacol Ther</source>. <year>2002</year>;<volume>72</volume>(<issue>2</issue>):<fpage>209</fpage>-<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr22-0091270010396711">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>AF</given-names></name>
<name><surname>Kroon</surname><given-names>R</given-names></name>
<name><surname>Schoemaker</surname><given-names>HC</given-names></name>
<name><surname>Breimer</surname><given-names>DD</given-names></name>
<name><surname>Van Vliet-Verbeek</surname><given-names>A</given-names></name>
<name><surname>Brandenburg</surname><given-names>HC</given-names></name>
</person-group>. <article-title>The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay</article-title>. <source>Br J Clin Pharmacol</source>. <year>1993</year>;<volume>35</volume>(<issue>2</issue>):<fpage>136</fpage>-<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr23-0091270010396711">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salphati</surname><given-names>L</given-names></name>
<name><surname>Benet</surname><given-names>LZ</given-names></name>
</person-group>. <article-title>Effects of ketoconazole on digoxin absorption and disposition in rat</article-title>. <source>Pharmacology</source>. <year>1998</year>;<volume>56</volume>(<issue>6</issue>):<fpage>308</fpage>-<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr24-0091270010396711">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sababi</surname><given-names>M</given-names></name>
<name><surname>Borga</surname><given-names>O</given-names></name>
<name><surname>Hultkvist-Bengtsson</surname><given-names>U</given-names></name>
</person-group>. <article-title>The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats</article-title>. <source>Eur J Pharm Sci.</source> <year>2001</year>;<volume>14</volume>(<issue>1</issue>):<fpage>21</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr25-0091270010396711">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Englund</surname><given-names>G</given-names></name>
<name><surname>Hallberg</surname><given-names>P</given-names></name>
<name><surname>Artursson</surname><given-names>P</given-names></name>
<name><surname>Michaelsson</surname><given-names>K</given-names></name>
<name><surname>Melhus</surname><given-names>H</given-names></name>
</person-group>. <article-title>Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring</article-title>. <source>BMC Med.</source> <year>2004</year>;<volume>2</volume>:<fpage>8</fpage>.</citation>
</ref>
<ref id="bibr26-0091270010396711">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fenner</surname><given-names>KS</given-names></name>
<name><surname>Troutman</surname><given-names>MD</given-names></name>
<name><surname>Kempshall</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug</article-title>. <source>Clin Pharmacol Ther.</source> <year>2009</year>;<volume>85</volume>(<issue>2</issue>):<fpage>173</fpage>-<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr27-0091270010396711">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>M</given-names></name>
<name><surname>Kang</surname><given-names>W</given-names></name>
</person-group>. <article-title>Inotropic effect of digoxin in humans: mechanistic pharmacokinetic/pharmacodynamic model based on slow receptor binding</article-title>. <source>Pharm Res.</source> <year>2004</year>;<volume>21</volume>(<issue>2</issue>):<fpage>231</fpage>-<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr28-0091270010396711">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Collett</surname><given-names>A</given-names></name>
<name><surname>Tanianis-Hughes</surname><given-names>J</given-names></name>
<name><surname>Carlson</surname><given-names>GL</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction</article-title>. <source>Eur J Pharm Sci.</source> <year>2005</year>;<volume>5</volume>:<fpage>386</fpage>-<lpage>393</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>